A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Or Metastatic Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Paticipants must have histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation. 2. Evidence of homozygous loss of CDKN2A (null) and/or MTAP (null) or lost MTAP expression in the tumor tissue. 3. MTAP-null and/or CDKN2A-null or lost MTAP expression solid tumor for which no standard therapy exists; or standard therapy has failed or not available/tolerated; or in the investigator’s opinion, standard therapy does not result in meaningful clinical benefit.

You may not be eligible for this study if the following are true:

  • 1. Presence of primary brain cancer. 2. Presence of hematological malignancy or lymphoma. 3.Spinal cord compression or active brain metastases or leptomeningeal disease from non-brain tumors. 4. History of other malignancy within the past 2 years, with the following exceptions: - Malignancy treated with curative intent and with no known active disease present for = 2 years before enrollment and felt to be at low risk for recurrence by the treating physician. - Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. - Adequately treated cervical carcinoma in situ without evidence of disease. - Adequately treated breast ductal carcinoma in situ without evidence of disease


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.